Press Release  AG Campbell Issues Statement On Supreme Court Ruling On Mifepristone

Boston — Massachusetts Attorney General Andrea Joy Campbell issued the following statement in response to today’s ruling by the Supreme Court of the United States in Louisiana v. FDA maintaining access to mifepristone, a safe and effective abortion medication: 

“Today’s decision preserves access to mifepristone as critical reproductive healthcare while this litigation continues. Mifepristone is one of the most common forms of safe and effective abortion care in Massachusetts and across the country, including for patients who rely on telehealth to access timely care,” said AG Campbell. “This decision ensures patients can continue making personal medical decisions without political interference. My office will continue to fight to preserve access in the face of this lawsuit and other threats.”  

On May 4, 2026, AG Campbell co-led a coalition of 22 states and the District of Columbia in filing an amicus brief in this case, urging the Supreme Court to stay a ruling by the U.S. Court of Appeals for the Fifth Circuit that would restrict access to mifepristone. AG Campbell and the coalition argued in their brief that the Fifth Circuit’s ruling was not supported by science, would create regulatory and administrative chaos nationwide, and would interfere with states’ ability to protect access to reproductive health care within their borders. 

Mifepristone, when used in combination with misoprostol, is the standard medication used to terminate a pregnancy through 10 weeks. Since the U.S. Food and Drug Administration (FDA) approved mifepristone in 2000, an estimated 7.5 million people in the United States have used the medication safely. Medication abortion now accounts for 63 percent of all abortions in the formal U.S. health care system, with approximately one in four abortions provided via telehealth. Studies have consistently found mifepristone to be safe and effective.   

###